GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer

Octavio Silva-García1, Ricarda Cortés-Vieyra2, Francisco N Mendoza-Ambrosio1

  • 1Departamento de Química Teórica, Universidad del Papaloapan, Oaxaca 68301, Mexico.

Biomolecules
|December 19, 2020
PubMed

Insights

Glycogen synthase kinase-3 alpha (GSK3α) plays a key role in neurodegenerative disorders and cancer. This review highlights GSK3α

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • Glycogen synthase kinase-3 (GSK3) exists as two paralogs, GSK3α and GSK3β, with overlapping and distinct functions.
  • Dysregulated GSK3 activity is implicated in neurodegenerative disorders (ND) and cancer.
  • Current inhibitors target both GSK3 paralogs, obscuring individual contributions and causing side effects due to numerous substrates.

Purpose of the Study:

  • To review the biological evidence for GSK3α's role in Alzheimer's disease (AD) and cancer.
  • To discuss strategies for developing GSK3α-specific inhibitors.

Main Methods:

  • Literature review of biological evidence.
  • Analysis of existing research on GSK3 paralogs and their inhibition.
  • Discussion of therapeutic strategies.

Main Results:

  • GSK3α is increasingly recognized as a primary driver in various diseases, including AD and cancer.
  • The specific roles of GSK3α versus GSK3β in disease pathogenesis are not fully elucidated.
  • Simultaneous inhibition of GSK3α and GSK3β leads to detrimental long-term effects.

Conclusions:

  • GSK3α is a significant therapeutic target in AD and cancer.
  • Paralog-specific inhibition of GSK3α is a promising strategy to mitigate side effects and enhance efficacy.
  • Further research into GSK3α-specific inhibition is warranted.